XXXX with synchronous liver metastases from @entity14 : Who will benefit from complete cytoreductive surgery?

@entity1 @entity137 @entity14 @entity298 @entity1349
PURPOSE: Selection of @entity1 for resection of synchronous liver metastases (LM) and @entity298 ( @entity298 ) of @entity14 ( @entity14 ) remains a debated issue since morbidity of this surgery is not negligible. We aimed to define @entity1349 ( @entity1349 ) prognostic criteria in @entity1 undergoing @entity298 surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and LM resection. METHODS: This monocentric and comparative study included all consecutive @entity1 operated for LM (LM group, n  =  77), @entity298 (HIPEC group, n  =  18) and @entity298  +  LM (LM  +  HIPEC group, n  =  9) from January 2007 to May 2011. Characteristics of the 3 groups were prospectively collected and retrospectively compared. RESULTS: Median follow-up was 56,5 months. Major morbidity and mortality were respectively 14% and 3%. Two-year disease free and @entity1349 rates were respectively 23% and 76%. There were significantly more Dindo grade III-IV complications in LM  +  HIPEC group. In multivariate analysis, grade II and III preoperative chemotherapy-induced @entity137 and size of LM were identified as poor @entity1349 prognostic factors whereas response to preoperative chemotherapy significantly increases @entity1349 . @entity1349 was not different (p  =  0.235) between the 3 groups. CONCLUSION: @entity137 to preoperative chemotherapy and size of LM were identified as poor prognostic factors in @entity1 undergoing simultaneous @entity298 and LM surgery. These criteria could help in better selecting @entity1 for such extensive surgery.
